{"commentary":{"count":5,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4,"youtube":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"IFm2022-01","nct_id":"NCT06353022","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ifm2022-01-nct06353022. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"IFm2022-01","arms":[{"description":"Patients treated with Teclistamab and Lenalidomide for finite duration.","label":"Teclistamab and Lenalidomide","type":"EXPERIMENTAL"},{"description":"Patients treated with Teclistamab and Talquetamab for finite duration","label":"Talquetamab andTeclistamab","type":"EXPERIMENTAL"}],"collaborators":["Janssen Pharmaceutica"],"completion_date":{"date":"2030-06-26","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":103,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Teclistamab","type":"DRUG"},{"name":"Talquetamab","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Bortezomib","type":"DRUG"},{"name":"Daratumumab","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"}],"last_update":"2026-03-17","lead_sponsor":"Nantes University Hospital","official_title":"Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-04-26","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Rate of sustained MRD negativity (NGS, 10^-5)","timeFrame":"38 months"},{"measure":"Rate of conversion from positive MRD to negative MRD (NGS, 10^-5)","timeFrame":"38 months"}],"references":[],"start_date":{"date":"2024-06-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT06353022"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ifm2022-01-nct06353022"}